Eplerenone
Product Images NDC 54868-6065

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Eplerenone (NDC 54868-6065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25 mg X 30 Tablets (Label)

Packaging label for Eplerenone 25 mg tablets distributed by Physicians Total Care, Inc. The label includes the product NDC 54868-6065-0, lot number, expiration date, and indicates manufacturing by Sandoz Inc. in Princeton, NJ. A barcode is also visible at the bottom of the label.*

FDA Label Image

Chemical Structure (9f5a0899 27eb 47b0 9ed5 Ede098fa410a 01)

Chemical structure of eplerenone showing the molecular framework with steroidal rings, ketone groups, and a methyl ester functional group. The diagram includes stereochemical indications of the molecule's three-dimensional arrangement.*

FDA Label Image

Figure 1 (9f5a0899 27eb 47b0 9ed5 Ede098fa410a 02)

A line graph showing cumulative incidence (%) over months since randomization for two treatment groups: Eplerenone and placebo. The graph plots the cumulative incidence on the vertical axis and months since randomization on the horizontal axis, with Eplerenone having a consistently lower cumulative incidence than placebo. Number of participants at risk for each group is shown below the time axis.*

FDA Label Image

Figure 2a (9f5a0899 27eb 47b0 9ed5 Ede098fa410a 03)

Two forest plot charts illustrating overall mortality hazard ratios with confidence intervals for Eplerenone versus placebo. The first chart analyzes subgroups by age, gender, and race, showing total number of events and patients. The second chart examines diabetes status, hypertension presence, and Killip class with respective patient and event counts.*

FDA Label Image

Figure 2b (9f5a0899 27eb 47b0 9ed5 Ede098fa410a 04)

Two forest plots depicting overall mortality in patient subgroups treated with Eplerenone. The first plot shows mortality stratified by creatinine clearance (mL/min) across four ranges. The second plot presents mortality by baseline use of beta blockers, ACE inhibitors, digoxin, and diuretics. Both plots compare hazard ratios for Eplerenone vs placebo with total number of events and patients noted.*

FDA Label Image

Figure 3 (9f5a0899 27eb 47b0 9ed5 Ede098fa410a 05)

A scatter plot chart illustrating the reduction in systolic blood pressure (SBP) in mmHg plotted against the dosage of Eplerenone tablets in mg/day. The chart compares results from two studies with different dosing regimens: Study 1 O_D, Study 2 O_D, and Study 2 B_I_D, each represented by distinct markers. The horizontal axis shows Eplerenone dosage ranging from 0 to 200 mg/day, while the vertical axis shows reductions in SBP from 0 to 16 mmHg.*

FDA Label Image

Figure 4 (9f5a0899 27eb 47b0 9ed5 Ede098fa410a 06)

A scatter plot graph showing reduction in diastolic blood pressure (mmHg) on the y-axis versus Eplerenone tablet dosage in mg/day on the x-axis. The graph includes data points from three groups: Study 1 QD, Study 2 QD, and Study 2 BID, distinguished by different marker shapes. The graph visualizes the relationship between Eplerenone dose and blood pressure reduction.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.